Harvard University, 1988, B.A. (cum laude, Biochemical Sciences)
University of Liverpool, School of Tropical Medicine, 1989, M.Sc. (Parasitology)
University of California, San Diego, 1997, Ph.D. (Biology)
University of California, San Diego, 1998, M.D.
University of Arizona, College of Public Health, 2016, M.P.H.
Residency: Internal Medicine, The Mayo Clinic
Fellowship: Medical Oncology, University of Arizona Cancer Center
Dr. Cranmer is board certified in Internal Medicine and Medical Oncology, and a practicing member in the Southwest Oncology Group. He is an expert in the clinical management of sarcoma, and melanoma and non-melanoma skin cancers. He has been directly involved in the design and/or execution of over 70 institutional-, industry- and national cooperative group-sponsored therapeutic clinical trials for melanoma and sarcoma patients, in addition to phase I solid tumor protocols. These have included trials of molecularly targeted therapies and immune-boosting therapies, such as immune checkpoint inhibitors. He treats patients at the Seattle Cancer Care Alliance, and is Director of the Bob and Eileen Gilman Family Sarcoma Clinic and Sarcoma Clinical Research Program at the Fred Hutchinson Cancer Research Center and University of Washington (UW). Dr. Cranmer is focused on supporting and expanding sarcoma research collaborations at Fred Hutch and UW, including the development of local clinical trials, involvement in national clinical trials, teaching and mentoring hematology-oncology fellows and community-outreach activities.
Dr. Cranmer has a variety of ongoing translational research interests. In melanoma, these include the biology of brain metastasis development, the biological significance of ulceration, and the significance of osteonectin and mutant B-Raf kinase expression in melanoma specimens. In sarcomas, he is investigating the activity of a number of novel anti-neoplastic agents in pre-clinical models, both alone and in combination with conventional chemotherapy agents, and working to understand the molecular basis of drug efficacy in these models.
Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery See details >
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma See details >
A Phase 2 Study of ABI-009 in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa) See details >